Cellectar Biosciences, Inc.
CLRBHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. At a $22.4M market cap, Cellectar Biosciences, Inc. ranks as a micro-cap company within healthcare. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Market Cap
$22.4M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-1.24
EPS (TTM)
$-2.21
EPS (Fwd)
$-1.92
ROE
-119.6%
ROA
-58.4%
Cash
$34.0M
Total Debt
$1.5M
Free CF
-$12.5M
52W Change
-55.2%
Annual Financials
Cash vs Debt
Where CLRB stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, CLRB finished 10.92% below its 150-day moving average ($2.84) and 14.24% below its 200-day moving average ($2.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLRB overbought or oversold?
At the August 31, 2026 close, CLRB's RSI(14) was 43.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cellectar Biosciences, Inc. holds $34.0M in cash against $1.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$12.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -119.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CLRB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cellectar Biosciences, Inc. and its sector.